Boards & Committees - Board of Directors
BOARD OF DIRECTORS
The ISHLT Board of Directors is comprised of 15 individuals: the four Officers (Past President, President, President-Elect, and Secretary-Treasurer) and eleven Directors, reflecting the geographic and disciplinary constituencies of the Society.
The Editor of the Journal of Heart and Lung Transplantion, the Medical Director of the Registry, the Annual Meeting Scientific Program Chair, the Chair of the Development Committee, and the Executive Director serve as ex-officio, non-voting members of the Board.
Newcastle Upon Tyne, UK
firstname.lastname@example.orgAndrew Fisher is Academic Director and Honorary Consultant Respiratory and Transplant Physician at the Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne and Professor of Respiratory Transplant Medicine at Newcastle University Medical School. He graduated from Nottingham University in 1993 and received research training as an Medical Research Council training fellow in Newcastle and Edinburgh 1996-99. He was subsequently awarded a GlaxoSmithKline Senior Clinical Research Fellowship 2005-2010. He has previously served as Chair of the British Thoracic Society Science and Research Committee 2009-2012 and Chair of the European Respiratory Society Lung Transplant Group 2010-2013.
Stanford University School of Medicine
Stanford, CA, USA
email@example.comJeffrey Teuteberg, MD, is an Assistant Professor of Medicine, Associate Director of the Cardiac Transplant Program, and a member of the Heart Failure/Cardiac Transplant section of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Medical Center, where he specializes in the care of patients with advanced cardiomyopathies, cardiac transplantation, ventricular assist devices and pulmonary hypertension. He has particular interests in advanced heart failure and the transition to cardiac transplantation and ventricular assist devices. Dr. Teuteberg graduated from the University of Chicago, Pritzker School of Medicine, in 1992 and remained at the University of Chicago for his Internal Medicine Residency and general Cardiovascular Fellowship, during which he spent a year as the Chief Medical Resident. Dr. Teuteberg received his Heart Failure and Cardiac Transplant training at Brigham and Women's hospital in Boston.
University of Wisconsin
Madison, WI, USA
firstname.lastname@example.orgMaryl R. Johnson, MD, received her medical degree from the University of Iowa College of Medicine where she also completed postgraduate training in Internal Medicine and Cardiovascular Diseases. She joined the faculty at Iowa and was instrumental in the establishment of a cardiac transplant program, serving as the Medical Director of Cardiac Transplantation from 1984-1988. Her subsequent career has been entirely devoted to the care of patients with heart failure and following cardiac transplantation. She served as the Associate Medical Director of the Cardiac Transplant Program at Loyola University Medical Center from 1988-1994, Associate Medical Director of the Rush Heart Failure and Cardiac Transplant Program from 1994-1997, and Medical Director, Heart Failure and Transplantation at Northwestern Memorial Hospital from 1998-2002. She moved to the University of Wisconsin as Medical Director of Heart Failure and Transplantation and Professor of Medicine in July 2002. Dr. Johnson's clinical interests are in the care of patients with severe congestive heart failure, including the use of mechanical circulatory support devices and cardiac transplantation. She has a particular interest in the treatment and outcome of congestive heart failure in women. Her research interests include the use of mechanical assistance in patients with severe heart failure and the coronary artery disease which develops in cardiac transplant recipients. She has also been an investigator in many of the multicenter trials evaluating new agents for the medical treatment of heart failure.
Duke University Medical Center
Durham, NC, USAjoseph.email@example.comJoseph Rogers is a Professor of Medicine at Duke University who specializes in adult cardiology, heart failure, heart transplant and mechanically assisted circulation. He obtained his medical degree from the University of Nebraska where he also performed his medical residency. He completed research and clinical cardiology training at Washington University in St. Louis prior to accepting a position as an attending cardiologist at Washington University and Barnes-Jewish Hospital. During his 10-year career at Washington University, he was the medical director of the cardiac transplant program. In 2004, he joined the faculty at Duke University and directed the cardiac transplant and mechanical circulatory support programs. His primary research interests include clinical trials in mechanically circulatory support and advanced heart failure.
Children's Hospital Medical Center
Cincinnati, OH, USAlara.firstname.lastname@example.orgLara Danziger-Isakov, MD, MPH, practices pediatric infectious diseases at Cincinnati Children's Hospital Medical Center where she is the Director of Pediatric Immunocompromised Host Infectious Diseases and Professor of Pediatrics at the University of Cincinnati. Dr. Danziger-Isakov earned her MD at Case Western Reserve University School of Medicine and complete her residency in Pediatrics at the Cleveland Clinic. She also completed a fellowship in Pediatric Infectious Diseases at St. Louis Children's Hospital and Washington University. Dr. Danziger-Isakov is board-certified in Pediatrics and Pediatric Infectious Diseases by the American Board of Pediatrics. Her clinical interests include pediatric infectious diseases, infections in transplant recipients, and infections in immunocompromised patients. Her research interests include outcomes related to infection after pediatric transplantation with an emphasis on pediatric and adult lung transplantation. In addition, Dr. Danziger-Isakov participates in clinical trials to evaluate new infectious disease therapies, new methods of detection for infectious diseases, and vaccination in immunocompromised hosts.DIRECTORS:
University of Michigan Health System
Ann Arbor, MI, USAkevichan@umich.eduKevin M. Chan, MD, is Professor of Medicine and Medical Director of the Lung Transplant program at the University of Michigan in Ann Arbor, MI, USA. He has been involved with lung transplantation since his fellowship training at the University of California Los Angeles and has also been associate director or director of lung transplantation at the University of Southern California and Henry Ford Hospital in Detroit. Dr. Chan’s primary research focus has been on post-transplant infections, improving patient outcomes and more recently, organ allocation policy development. He has been involved with the United Network for Organ Sharing (UNOS)/Organ Procurement and Transplant Network (OPTN) in various volunteer capacities over the years. Dr. Chan is the Fellowship Director for Pulmonary and Critical Care Medicine at the University of Michigan and has been a previous Scientific Program Chair as well as a leader in other professional organizations. He brings his expertise in clinical lung transplantation, policy development, organizational understanding and medical education to the ISHLT.
University of Pennsylvania
Philadelphia, PA, USA
email@example.comJason D. Christie, M.D., M.S. is the Chief of the Pulmonary, Allergy, and Critical Care Division. He is Professor of Medicine in the Department of Medicine and Professor of Epidemiology in the Department of Biostatistics and Epidemiology at the University of Pennsylvania. He is a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. His career is focused on translational research studies of the risks, pathogenesis, treatment, and outcomes of acute lung injury (ALI) in the transplant and non-transplant human populations. Through leadership of the Center for Translational Lung Biology, Dr. Christie brings together clinicians, bench scientists, epidemiologists, and statisticians to build multidisciplinary research teams. His research integrates new knowledge generated from bench studies with epidemiology approaches in well-phenotyped, large human populations to generate new definitions of human syndromes, improved diagnostics and prognostics, and targeted therapy approaches in advanced lung diseases and critical illness.
Dr. Christie is the founder of the lung transplant outcomes group (LTOG), which is a multicentered cohort study the etiology and pathogenesis of acute lung injury following lung transplantation (termed primary graft dysfunction). This line of research is funded by multiple R01 grants from NHLBI; active LTOG research themes focus on the mechanisms of clinical factors that elevate PGD risk, including donor smoke exposure, recipient obesity and body composition, pulmonary hypertension, alterations in lung microbiome, and autoimmunity to lung collagens. His multidisciplinary lung transplant research focuses on genetics, innate immunity, regulatory T-cells, innate lymphoid cell (ILC) populations in the lung, ischemia reperfusion injury, inflammation, and autoimmunity.
St. Vincent's Heart Center of Indiana
Indianapolis, IN, USA
734-546-4911Jennifercowger@gmail.comDr. Jennifer Cowger is the medical director of the Henry Ford Mechanical Circulatory Support Program in Detroit, Michigan. She has a masters in biostatistics & clinical trial design from the University of Michigan and is the chair of the IMACS research committee and is on the DAAP Committee of INTERMACS. She joined the ISHLT board of directors in 2017 and is a liaison for the Education committee.
University of California, San Francisco
San Francisco, California, USA
firstname.lastname@example.orgTeresa De Marco, MD , completed her internal medicine residency and cardiology fellowship at the University of California, San Francisco (UCSF). She completed training in heart transplantation at the University of Utah Medical Center in 1989 and since then has been on the faculty at UCSF. She is Board Certified in Internal Medicine, Cardiovascular Medicine and Advanced Heart Failure/Transplant Cardiology. She is currently Professor of Medicine and Surgery. She holds the R.H. and Jane G. Logan Endowed Chair in Cardiology. She is the Director of the Advanced Heart Failure Therapies Program and Medical Director of Heart Transplantation. She is Director of the Adult Pulmonary Hypertension Comprehensive Care Center. She serves as Director of the Advanced Heart Failure and Transplant Cardiology Fellowship Program.
She has authored or co-authored over 150 publications. Since 1989, Dr. De Marco has participated in over 30 clinical research trials. She has served on a multitude of national and international steering, events, and data monitoring committees for clinical research trials in heart failure, pulmonary hypertension and device therapies. She has chaired numerous scientific symposia, has lectured extensively at medical institutions, and has been a frequently invited international speaker. Dr. De Marco is a member of multiple societies including the International Society of Heart and Lung Transplantation (ISHLT). She has served as the Pulmonary Hypertension Council representative on the Standards and Guidelines Committee and on the ISHLT Program Committee. She served as the 2016 Chair of the ISHLT Academy Core Competencies Course in Heart Failure and Cardiac Transplant Medicine.
University of California - San Francisco
San Francisco, CA, USATobias.Deuse@ucsf.eduTobias Deuse is Transplant and MCS Surgeon at the University of California San Francisco. He completed his cardiothoracic residency in Munich and Hamburg, and completed a fellowship in Thoracic Transplantation and Mechanical Circulatory Support at Stanford University. His main clinical interests are minimally-invasive lung transplantation and minimally-invasive LVAD implantation. His research focus includes the development of new immunosuppressive/ immunomodulatory agents and alternative forms of administration like inhaled immunosuppression or cell-based immunomodulation. He is also active in the field of pluripotent stem cell research and tissue regeneration.
Drexel University College of Medicine
Philadelphia, PA, USAheisen@drexelmed.eduHoward J. Eisen, MD was born in Queens, New York and was graduated with an AB degree cum laude with distinction in all subjects and Phi Beta Kappa from the Cornell University College of Arts and Sciences in 1977. He received his MD from the University of Pennsylvania School of Medicine in 1981 and was elected to Alpha Omega Alpha. He did his Internal Medicine residency at the Hospital of the University of Pennsylvania. He then did his Cardiovascular Fellowship at Washington University in St. Louis/Barnes Hospital and completed this training in 1987. He was then an Assistant Professor of Medicine and Medical Co-Director of the Cardiac Transplant Program at the University of Pennsylvania. In 1993, he moved to the Temple University School of Medicine to be Medical Director of the Heart Failure and Cardiac Transplant Program which became one of the largest in the country. He rose to the rank of Professor of Medicine and Physiology at Temple. In 2005, Dr. Eisen was appointed Thomas J. Vischer Professor of Medicine and Chief of the Division of Cardiology at the Drexel University College of Medicine and Hahnemann University Hospital. He subsequently also was installed as the Joseph DiPalma MD Famaily Professor of Cardiology. Dr. Eisen is an Associate Editor of the American Journal of Transplantation and Transplantation and a Deputy editor the Journal of Clinical Transplantation. He is on the Editorial Board of the Journal of the American College of Cardiology Heart Failure,the Journal of Heart and Lung Transplantation and the Journal of Cardiac Failure. Dr. Eisen has led several clinical trials in cardiac transplant recipients including the everolimus clinical trials and has been involved in the development of gene expression profiling in cardiac transplant patients. He has chaired AHA research study sections and has been a member of NIH study sections. Dr. Eisen’s research has been funded by the American Heart Association of which he was an Established Investigator, the NIH and industry.
Heart and Diabetes Center NRW
Bad Oeynhausen, GERMANY
05731 / 97 email@example.comStephan Ensminger, M.D., D.Phil. is a Professor of Cardiothoracic Surgery and one of the Deputy Heads of the Department of Thoracic and Cardiovascular Surgery at the Heart and Diabetes Center NRW, Ruhr University Bochum at Bad Oeynhausen, Germany. Dr. Ensminger graduated from the University of Würzburg Medical School in 1996, followed by an internship in Cardiothoracic Surgery at the University of Tübingen, Germany and a D.Phil. in Transplantation Immunology at the Nuffield Department of Surgery at the University of Oxford, U.K. under the supervision of Prof. Kathryn Wood in 2000. He received his cardiothoracic surgery training at the University of Erlangen-Nürnberg, Germany, where he was appointed as a Professor of Experimental Cardiac Surgery in 2008. His particular interests are Transplantation Immunology with the main focus on the immunobiology of cardiac allograft vasculopathy (CAV) and minimally invasive cardiac surgery with the emphasis on catheter based valve therapies (TAVR). He is currently a member of the executive board of the German Society of Thoracic and Cardiovascular Surgery and the German Aortic Valve Registry (GARY).
Montefiore Medical Center
Bronx, New York, USA
firstname.lastname@example.orgDr. Daniel J. Goldstein is a Professor at the Albert Einstein College of Medicine and Vice Chairman of the Department of Cardiothoracic Surgery at Montefiore Medical Center in New York where he also serves as the Director of the Mechanical Assistance Program. He is a graduate of the Mount Sinai School of Medicine (1991) and completed his general surgery and cardiothoracic surgery training at Columbia Presbyterian Medical Center in New York in 2000. While clinically active in all aspects of adult cardiothoracic surgery including coronary, valvular and aneurysmal heart disease, his clinical and research interests focus on the surgical management of end stage heart disease including stem cell therapies and pharmacological adjuncts for induction of left ventricular recovery in patients supported with left ventricular assist devices. Dr. Goldstein is an active member of the INTERMACS adverse event committee and has partaken as principal site investigator in multiple industry-based and NIH-supported clinical ventricular assist device trials.
The Prince Charles Hospital
61-7-3350-8111Peter_Hopkins@health.qld.gov.auDr Peter Hopkins is the Director of the Queensland Lung Transplant Service and Associate Professor with the School of Medicine, University of Queensland, Brisbane. Research interests include First in Man clinical trials of innovative bronchoscopic techniques of lung volume reduction and development of novel treatment strategies for interstitial lung disease. Executive positions are held with the Australian Lung Foundation (PIVOT and the Australian IPF Registry), Deputy Chair of the Lung Standing Committee Transplant Society of Australia and New Zealand, Convenor SIG Interventional Bronchoscopy Thoracic Society of Australia and New Zealand and National Examiners Panel Royal Australian College of Physicians.
University of Minnesota Medical Center
Minneapolis, MN, USA
email@example.comDr. Michael Petty is the Cardiothoracic Clinical Nurse Specialist at the University of Minnesota Medical Center, Minneapolis, MN. He received his initial nursing degree from St. Mary’s Junior College, Minneapolis, MN, and subsequently obtained a Bachelors Degree in Nursing from the University of the State of New York, and a Masters Degree and PhD in Nursing from the University of Minnesota. He began his career as a staff nurse in the Surgical ICU at the University of Minnesota Hospital and Clinic, and has held a variety of clinical, administrative, and industry roles in the subsequent years. Much of his focus and interest during that time has been in the care of patients with cardiovascular disorders requiring medical, surgical, and transplant interventions. He has been an active participant in the Mechanical Circulatory Support community since 1995 including serving as president of the International Consortium of Circulatory Assist Clinicians (ICCAC) in 2013. His clinical research interests focus on thoracic transplant and family caregivers of MCS patients.
University Hospital Gasthuisberg
firstname.lastname@example.orgDirk Van Raemdonck, MD, PHD, is a Professor of Surgery at the Katholieke Universiteit Leuven and Chair of the Leuven University Hospitals Transplant Center, Leuven, Belgium. As a General Thoracic Surgeon he currently serves as the Surgical Director of the Leuven Lung Transplant Program.
He graduated as MD from the Katholieke Universiteit Leuven in 1984. He finished his training in general surgery in 1990 and in thoracic surgery in 1992. He was a registrar in thoracic surgery at the East Birmingham Hospital, Birmingham, U.K in 1990 (Prof HR Matthews), research fellow at the Memorial Sloan-Kettering Cancer Center, New York, N.Y. in 1991 (Dr RJ Ginsberg), and cardiothoracic transplant fellow at the Freeman Hospital, Newcastle-upon-Tyne, U.K. in 1991 (Prof JH Dark). He obtained his PHD degree from the Katholieke Universiteit Leuven in 1998. His main research topic is lung transplantation with particular interest in primary graft dysfunction, donation from donors after circulatory death, and ex-vivo lung perfusion.
He is a current Board member A of Eurotransplant International Foundation since 2005 and previously served as the President of the European Society of Thoracic Surgeons (2012-2013) and as chair of the Thoracic Committee within the European Society for Organ Transplantation (2006-2012).EX-OFFICIO BOARD MEMBERS:
14673 Midway Rd., Suite 200
Addison, Texas, 75001
email@example.comBio coming soon...
Members of the 2017-2018 ISHLT Board of Directors convened in April 2017 at the ISHLT Annual Meeting in San Diego, CA.